投资策划网—规模最大、实力最强的研究报告提供商! 关于我们 联系中撰 网站地图
稳评报告
当前位置:主页 > 稳评报告 > >> China Genetic Engineering Drug Industry Report, 2012-2016
China Genetic Engineering Drug Industry Report, 2012-2016
2012-07-12 09:46共有人浏览
更多
内 容
 

 

【Table of Contents】

1 Profile of Biopharmaceutical Industry
1.1 Definition and Classification
1.2 Genetic Engineering Drugs

2 Overview of China Genetic Engineering Drug Industry
2.1 Global Market
2.2 Development Status
2.3 Competition Pattern
2.4 Prospects and Dynamics

3 Genetic Engineering Drug Market Segments in China
3.1 Monoclonal Antibody
3.1.1 Status Quo
3.1.2 Competition Pattern
3.1.3 Prospects and Dynamics
3.2 Recombinant Human Erythropoietin
3.2.1 Status Quo
3.2.2 Competition Pattern
3.2.3 Prospects and Dynamics
3.3 Recombinant Human Interferon
3.3.1 Status Quo
3.3.2 Competition Pattern
3.3.3 Prospects and Dynamics
3.4 Recombinant Human Growth Hormone
3.4.1 Status Quo
3.4.2 Competition Pattern
3.4.3 Prospects and Dynamics
3.5 Recombinant Human Insulin
3.5.1 Status Quo
3.5.2 Competition Pattern
3.5.3 Prospects and Dynamics
3.6 Others
3.6.1 Recombinant Human Coagulation Factor
3.6.2 Recombinant Human Granulocyte-Colony Stimulating Factor
3.6.3 Interleukin

4 Key Manufacturers in China
4.1 Shanghai Lansheng Guojian Pharmaceutical Co., Ltd
4.1.1 Profile
4.1.2 Shanghai CP Guojian Pharmaceutical Co., Ltd
4.2 Biotech Pharmaceutical Co., Ltd
4.2.1 Profile
4.2.2 Competition Advantages
4.2.3 R&D of Monoclonal Antibody Drugs
4.3 Anhui Anke Biotechnology (Group) Co., Ltd
4.3.1 Profile
4.3.2 Operation
4.3.3 Revenue Structure
4.3.4 Gross Margin
4.3.5 Clients and Suppliers
4.3.6 R&D and Investment
4.3.7 Genetic Engineering Drugs
4.4 GeneScience Pharmaceuticals Co., Ltd
4.4.1 Profile
4.4.2 Operation
4.4.3 R&D and Investment
4.5 Beijing SL Pharmaceutical Co., Ltd
4.5.1 Profile
4.5.2 Operation
4.5.3 Revenue Structure
4.5.4 Gross Margin
4.5.5 R&D and Investment
4.5.6 Genetic Engineering Drugs
4.6 Jiangsu Sihuan Bioengineering Co., Ltd
4.6.1 Profile
4.6.2 Operation
4.6.3 Genetic Engineering Drugs
4.6.4 Beijing Four Rings Bio-Pharmaceutical Co., Ltd
4.7 Shenzhen Neptunus Interlong Bio-Technique Co., Ltd
4.7.1 Profile
4.7.2 Operation
4.7.3 Genetic Engineering Drugs
4.8 3SBio Inc.
4.8.1 Profile
4.8.2 Operation
4.8.3 Revenue Structure
4.8.4 R&D and Investment
4.9 Tonghua Dongbao Pharmaceutical Co., Ltd
4.9.1 Profile
4.9.2 Operation
4.9.3 Revenue Structure
4.9.4 Gross Margin
4.9.5 Clients and Suppliers
4.9.6 Genetic Engineering Drugs
 

【Figures & Tables】

Classification of Biopharmaceutical Products
Classification of Genetic Engineering Drugs
Sales of Amgen’s Four Genetic Engineering Drugs, 2009-2011
R&D Cost of Main Biopharmaceutical Enterprises in the World, 2009-2011
Competition Pattern of Genetic Engineering Drugs in China, 2011
Comparison between China, USA and Japan by Commercialization Schedule of Some Genetic Engineering Protein Drugs
Expiration Date of Main Genetic Engineering Drug Patents in the World
Monoclonal Antibody Drugs Approved for Marketing in China, As of 2012
Sales of Monoclonal Antibody Drugs in China, 2008-2011
Some Listed Companies Investing in Monoclonal Antibody Industry in China, 2009-2012
Sales Volume and Value of EPO in China, 1999-2011
Competition Pattern of EPO in China (by Sales Volume or Value), 2007-2011
Market Size of rh-IFN in China, 2006-2011
Market Share of Major rh-IFN Injection Enterprises in China by Sales, 2006-2008
Market Capacity Forecast of rh-IFN for Hepatitis Therapy in China
Comparison Between Long-acting IFN and Conventional IFN
Market Share of Major rh-GH Enterprises in China, 2006-2008
Market Capacity Forecast of rh-GH for Short Stature Therapy in China
Market Prices of Common Insulin Products in China, 2010-2011
Lot Release Volume and Its Growth Rate of Coagulation Factor VIII in China, 2008-2011 Market Share of rhG-CSF Enterprises in China, 2010
Major Monoclonal Antibody Product Line under Research of Shanghai Lansheng Guojian Pharmaceutical
Revenue and Net Income of Shanghai CP Guojian Pharmaceutical, 2008-2010
Monoclonal Antibody Product Series under Research of Shanghai CP Guojian Pharmaceutical
Under-research Monoclonal Antibody Projects of Beijing Biotech
Revenue and Profit of ANKE BIO, 2007-2011
ANKE BIO’s Revenue Breakdown by Industry, 2007-2012
ANKE BIO’s Revenue Percentage by Industry, 2007-2012
ANKE BIO’s Revenue Breakdown by Region, 2007-2011
ANKE BIO’s Revenue Percentage by Region, 2007-2011
ANKE BIO’s Gross Margin by Industry, 2007-2011
ANKE BIO’s Revenue from Top 5 Clients and % of Total Revenue, 2007-2011
Name List and Revenue Contribution of ANKE BIO’s Top 5 Clients, 2011
ANKE BIO’s Procurement from Top 5 Suppliers and % of Total Procurement, 2007-2011
R&D Costs and % of Total Revenue of ANKE BIO, 2007-2011
ANKE BIO’s Revenue from Interferon and Growth Hormone, 2007-2011
ANKE BIO’s Gross Margin from Interferon and Growth Hormone, 2007-2011
Revenue and Operating Income of GenSci, 2009-2011
Research Schedule of GenSci’s Genetic Engineering Drugs, As of 2011
Revenue and Operating Income of SL Pharmaceutical, 2007-2012
SL Pharmaceutical’s Revenue and Procurement from Top5 Clients and Suppliers, 2008-2011
SL Pharmaceutical’s Revenue Breakdown by Products, 2008-2011
SL Pharmaceutical’s Revenue Percentage by Products, 2008-2011
SL Pharmaceutical’s Revenue Breakdown by Region, 2008-2011
SL Pharmaceutical’s Gross Margin by Products, 2008-2011
R&D Costs and % of Total Revenue of SL Pharmaceutical, 2008-2011
Revenue and Operating Income of Sihuan Bioengineering, 2008-2012
Sihuan Bioengineering’s Operating Revenue by Region, 2008-2011
Sihuan Bioengineering’s Revenue from Interleukin and EPO, 2008-2011
Sihuan Bioengineering’s Gross Margin from Interleukin and EPO, 2008-2011
Revenue and Profit of Beijing Four Rings, 2008-2011
Revenue and Profit of Neptunus Interlong Bio-Technique, 2008-2012
Neptunus Interlong Bio-Technique’s Revenue Breakdown by Business, 2008-2011
Products List of 3SBio Inc.
Revenue and Profit of 3SBio Inc., 2007-2012
3SBio Inc.’s Revenue Breakdown by Product/Region, 2009-2012
3SBio Inc.’s Revenue Percentage by Products, 2009-2011
3SBio Inc.’s Revenue Percentage by Region, 2009-2012
R&D Cost of 3SBio Inc. by Products, 2009-2011
Research Schedule of 3SBio Inc. , As of Mar., 2012
Revenue and Profit of THDB, 2008-2012
THDB’s Revenue Breakdown by Products, 2008-2011
THDB’s Revenue Percentage by Products, 2008-2011
THDB’s Revenue Breakdown by Region, 2008-2011
THDB’s Revenue Percentage by Region, 2008-2011
THDB’s Gross Margin by Products, 2008-2011
THDB’s Revenue from Top 5 Clients and % of Total Revenue, 2008-2011
Name List and Revenue Contribution of THDB’s Top 5 Clients, 2011
Revenue and Gross Margin of THDB’s Recombinant Human Insulin, 2008-2011
Research Schedule of Amoytop Biotech’s Long-acting Recombinant Protein Drugs, As of 2011

  •  

【编辑:中国投资政策网】 TOP
专项定制报告专项定制报告分类
专项报告类别:
商业计划书 | 可行性研究报告 | 资金申请报告
可行性报告 | 项目申请报告 | 英文报告
联系方式
·联系人:
余先生、方小姐
·电话号码:
15989039303、(0086)020-28908140
·地址:
广州市番禺区桥南街福德路241号奥园广场塔三1305室

订购流程订购流程
① 签订可行性报告订购合同;
② 通过银行转帐、邮局汇款等形式款项;
③ 中国投资策划网见到汇款底单或者转帐底单后,24小时内发送可行性研究报告电子版,72小时内寄送正式版以及发票。